Výsledky vyhledávání

Akademický článek

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Autor: A. Deodhar, P. J. Mease, I. B. McInnes, X. Baraliakos, K. Reich, A. Blauvelt, C. Leonardi, B. Porter, A. Das Gupta, A. Widmer, L. Pricop, T. Fox

Publikováno v: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-11 (2019)

Abstract Background Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis

Externí odkaz: https://doaj.org/article/993397c83abf4290baa620330d69955a

Zobrazit plný text záznamu

Akademický článek

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

Autor: Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi, Alessandro Di Federico, Mark M. Awad, Maria K. Lehtinen, Marian H. Harris, Roberto Chiarle

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)

Abstract Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as a mechanism of resistance to targeted therapy. Partner genes and exons in most TK fusions are followed typical recurrent patterns, but the underl

Externí odkaz: https://doaj.org/article/f91a851ffb1747f5bdae9ea30cb198bb

Zobrazit plný text záznamu

Akademický článek

Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy

Autor: Lars J. Isaksson, Matteo Pepa, Mattia Zaffaroni, Giulia Marvaso, Daniela Alterio, Stefania Volpe, Giulia Corrao, Matteo Augugliaro, Anna Starzyńska, Maria C. Leonardi, Roberto Orecchia, Barbara A. Jereczek-Fossa

Publikováno v: Frontiers in Oncology, Vol 10 (2020)

In order to limit radiotherapy (RT)-related side effects, effective toxicity prediction and assessment schemes are essential. In recent years, the growing interest toward artificial intelligence and machine learning (ML) within the science community

Externí odkaz: https://doaj.org/article/75576e930e4a4607b6f401cea6ce7a4c

Zobrazit plný text záznamu

Akademický článek

Ageing: from inflammation to cancer

Autor: Giulia C. Leonardi, Giulia Accardi, Roberto Monastero, Ferdinando Nicoletti, Massimo Libra

Publikováno v: Immunity & Ageing, Vol 15, Iss 1, Pp 1-7 (2018)

Abstract Ageing is the major risk factor for cancer development. Hallmark of the ageing process is represented by inflammaging, which is a chronic and systemic low-grade inflammatory process. Inflammation is also a hallmark of cancer and is widely re

Externí odkaz: https://doaj.org/article/fb67f423380b49df9bb7e873a4ea4e27

Zobrazit plný text záznamu

Plný text ve formátu HTML

Supplementary Methods from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Detailed description of methodology and reagents

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37969b8d5e0762e7d773b7b6d2aee3e3
https://doi.org/10.1158/1078-0432.22469682

Zobrazit plný text záznamu

Suppl. Figure S2 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Next generation sequencing copy number plots for Case #2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3503cca1311b251af5a159338aab0305
https://doi.org/10.1158/1078-0432.22469700.v1

Zobrazit plný text záznamu

Suppl. Table S1 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Antibodies, compounds, oligonucleotides, and other reagents used in the study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b79e7746eb47f3b0b13d453a04af31
https://doi.org/10.1158/1078-0432.22469688.v1

Zobrazit plný text záznamu

Supplementary Data from Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Supplementary Figure Legends

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1328adafccdfbb4d67dca43a18bdab9e
https://doi.org/10.1158/1078-0432.22478466.v1

Zobrazit plný text záznamu

Data from Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Purpose:Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact on sequential MET TKI the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9f6f735866b3000aecf2169c24f8cc
https://doi.org/10.1158/1078-0432.c.6529956

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání